Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumors

Por Piha-Paul, S.A., Munster, P.N., Hollebecque, A., Argilés, G., Dajani, O., Cheng, J.D., Wang, R., Swift, A., Tosolini, A., Gupta., S.
Publicado no Eur J Cancer (2015)

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Por von Mehren, M., Schilder, R. J., Cheng, J. D., Temmer, E., Cardoso, T. M., Renshaw, F. G., Bayever, E., Zannikos, P., Yuan, Z., Cohen, R. B.
Publicado em 2008

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibit...

Por Brana, I, Berger, R, Golan, T, Haluska, P, Edenfield, J, Fiorica, J, Stephenson, J, Martin, L P, Westin, S, Hanjani, P, Jones, M B, Almhanna, K, Wenham, R M, Sullivan, D M, Dalton, W S, Gunchenko, A, Cheng, J D, Siu, L L, Gray, J E
Publicado no Br J Cancer (2014)